脑血疏口服液对急性脑出血患者的临床疗效及对神经功能和生活能力的影响

Clinical efficacy of Naoxueshu Oral Liquid on patients with acute cerebral hemorrhage and its effects on neurological function and activities of daily living

关键词:  急性脑出血  脑血疏口服液  临床疗效  神经功能  生活能力

Key words:  acute cerebral hemorrhage  Naoxueshu Oral Liquid  clinical efficacy  neurological function  activities of daily living

摘要:

[目的] 探究脑血疏口服液对急性脑出血患者的临床疗效及对神经功能和生活能力的影响。[方法] 选取2023年4月—2025年4月多中心收治的急性脑出血患者398例。根据治疗方案分为观察组250例和对照组148例。对照组给予降颅内压、镇静吸氧等内科常规对症治疗，观察组在对照组的基础上给予脑血疏口服液治疗，随访3个月。比较两组的临床疗效、神经功能和生活能力，统计不良事件发生情况。[结果] 观察组临床疗效有效率为88.80%，高于对照组80.41%（P＜0.05）。发病7、14 d，两组美国国立卫生研究院卒中量表（NIHSS）评分较发病前均降低，观察组低于对照组（P＜0.05）；发病14 d，两组NIHSS评分均低于发病7 d时评分，观察组低于对照组（P＜0.05）。发病1、3个月，观察组改良RANKIN量表（mRS）评分均低于对照组（P＜0.05）。发病1、3个月，两组日常生活活动能力量表（BI）评分较发病14 d时评分均升高（P＜0.05）；发病3个月，两组BI评分较发病1个月时评分均升高（P＜0.05）；发病14 d和发病1、3个月，观察组BI评分均高于对照组（P＜0.05）。随时间延长，两组简易精神状态评价量表（MMSE）评分逐渐升高，但差异无统计学意义（P＞0.05）；发病14 d和发病1、3个月，观察组MMSE评分均高于对照组（P＜0.05）。随访3个月期间，两组均无死亡病例；观察组不良反应发生率为6.00%，低于对照组14.86%（P＜0.05）。[结论] 脑血疏口服液用于急性脑出血患者，临床疗效良好，能够显著促进神经功能恢复，提升其生活能力和认知功能，且安全性好。

Abstract:

[Objective] To explore the clinical efficacy of Naoxueshu Oral Liquid in patients with acute intracerebral hemorrhage and its impact on neurological function and activities of daily living. [Methods] A total of 398 patients with acute intracerebral hemorrhage treated at multiple centers from April 2023 to April 2025 were selected. Based on the treatment plan，they were divided into the observation group（250 cases） and the control group（148 cases）. The control group received routine symptomatic treatments，including intracranial pressure reduction，sedation，and oxygen therapy. The observation group received Naoxueshu Oral Liquid in addition to the treatment provided to the control group. Both groups were followed up for 3 months. The clinical efficacy，neurological function，and activities of daily living were compared between the two groups，and the incidence of adverse events was recorded. [Results] The clinical efficacy rate of the observation group was 88.80%，higher than that of the control group（80.41%），P＜0.05. At 7 and 14 days post-onset，the National Institutes of Health Stroke Scale（NIHSS） scores of both groups were lower than those before onset，with the observation group showing lower scores than the control group（P＜0.05）. At 14 days post-onset，both groups had lower NIHSS scores compared to the scores at 7 days post-onset，with the observation group again having lower scores than the control group（P＜0.05）. At 1 and 3 months post-onset，the modified Rankin Scale（mRS） scores of the observation group were lower than those of the control group（P＜0.05）. At 1 and 3 months post-onset，both groups had improved scores on the Barthel Index（BI） compared to the 14-day scores（P＜0.05）. At 3 months post-onset，both groups had increased BI scores compared to 1 month post-onset（P＜0.05）. The BI scores of the observation group were higher than those of the control group at 14 days，1 month，and 3 months post-onset（P＜0.05）. Over time，both groups showed a gradual increase in the Mini-Mental State Examination（MMSE） scores，but there were no statistically significant differences（P>0.05）. However，at 14 days，1 month，and 3 months post-onset，the MMSE scores of the observation group were higher than those of the control group（P＜0.05）. No deaths were reported in either group during the 3-month follow-up period. The incidence of adverse reactions in the observation group was 6.00%，significantly lower than the 14.86% in the control group（P＜0.05）. [Conclusion] Naoxueshu Oral Liquid is effective for patients with acute intracerebral hemorrhage，with significant improvement in clinical efficacy，neurological function，activities of daily living，and cognitive function. It also demonstrates good safety.